Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review | Zendy

Anastasios Kyriazoglou | Zendy; Maria Kaparelou | Zendy; Georgios Goumas | Zendy; Michalis Liontos | Zendy; Roubini Zakopoulou | Zendy; Eleni Zografos | Zendy; Anna Zygogianni | Zendy; Meletios Α. Dimopoulos | Zendy; Flora Zagouri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Author(s) -

Anastasios Kyriazoglou,

Maria Kaparelou,

Georgios Goumas,

Michalis Liontos,

Roubini Zakopoulou,

Eleni Zografos,

Anna Zygogianni,

Meletios Α. Dimopoulos,

Flora Zagouri

Publication year - 2021

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000514860

Subject(s) - medicine , breast cancer , immunotherapy , oncology , trastuzumab , cancer , gynecology

The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data. Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer. Results: Twelve clinical trials and 2 case reports were identified in our study. Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research